Business Context and Reporting Period
Company: Histogenics Corporation (Note: Metadata lists "Ocugen, Inc.", but the filing text identifies the registrant as Histogenics Corporation).
Filing Type: Form 8-K (Current Report).
Date of Report: May 3, 2016.
Event: The Company disclosed clerical errors in its 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan (ESPP) regarding maximum share issuance limits per participant. These errors resulted from the inadvertent application of a reverse stock split. The filing re-files corrected versions of these plans and updates disclosures previously made in the April 28, 2016 Proxy Statement.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on equity compensation plan terms and share reserves.
| Metric | Value |
|---|---|
| 2013 Plan Total Share Reserve (including proposed amendment) | 1,869,957 shares |
| Shares Subject to Outstanding Options (as of April 25, 2016) | 1,026,662 shares |
| Weighted Average Exercise Price (Outstanding Options) | $6.59 |
| Shares Available for Future Issuance (2013 Plan) | 363,705 shares |
| 2013 ESPP Initial Share Reserve | 103,665 shares |
Material Changes and Plan Amendments
Correction of Clerical Errors: The Company corrected errors in the 2013 Plan and 2013 ESPP related to the maximum number of shares a participant may receive or purchase in a calendar year.
Proposed Amendment to 2013 Plan: The Board approved an amendment subject to stockholder vote at the June 22, 2016 Annual Meeting. If approved, the amendment will:
- Increase the aggregate shares available for issuance under the 2013 Plan by 300,000 shares.
- Increase the automatic annual share reserve addition starting January 1, 2017, to the lesser of 4.0% of outstanding shares or a Board-determined number.
Automatic Director Grants: Non-employee directors receive automatic options (20,000 shares initially, 10,000 shares annually) vesting over 3 years and 12 months, respectively.
Outlook, Risks, and Contingencies
Stockholder Approval Contingency: The proposed increase of 300,000 shares to the 2013 Plan is contingent upon stockholder approval at the June 22, 2016 Annual Meeting. If not approved, the corrected existing plan remains in effect.
Change in Control Provisions: The plans include provisions for acceleration of vesting or cash settlement in the event of a change in control (defined as acquisition of >50% voting power, sale of substantially all assets, or merger resulting in <50% voting power for the Company).
Plan Termination: The 2013 Plan expires in ten years unless extended. The 2013 ESPP terminates 20 years after adoption unless extended.
Key Facts for Investor Verification
- Verify the outcome of the stockholder vote on the 2013 Plan amendment at the June 22, 2016 Annual Meeting.
- Confirm the corrected share limits for participants in the 2013 Plan and 2013 ESPP to ensure compliance with the filing.
- Monitor the weighted average exercise price of outstanding options ($6.59) relative to the current market price to assess dilution risk.
- Review the full text of the corrected 2013 Plan (Exhibit 10.3) and 2013 ESPP (Exhibit 10.4) for specific vesting schedules and forfeiture terms.